294 related articles for article (PubMed ID: 30502626)
1. 1,3,4-oxadiazole/chalcone hybrids: Design, synthesis, and inhibition of leukemia cell growth and EGFR, Src, IL-6 and STAT3 activities.
Fathi MAA; Abd El-Hafeez AA; Abdelhamid D; Abbas SH; Montano MM; Abdel-Aziz M
Bioorg Chem; 2019 Mar; 84():150-163. PubMed ID: 30502626
[TBL] [Abstract][Full Text] [Related]
2. Design and synthesis of novel quinoline/chalcone/1,2,4-triazole hybrids as potent antiproliferative agent targeting EGFR and BRAF
Mohassab AM; Hassan HA; Abdelhamid D; Gouda AM; Youssif BGM; Tateishi H; Fujita M; Otsuka M; Abdel-Aziz M
Bioorg Chem; 2021 Jan; 106():104510. PubMed ID: 33279248
[TBL] [Abstract][Full Text] [Related]
3. EGFR inhibitors and apoptotic inducers: Design, synthesis, anticancer activity and docking studies of novel xanthine derivatives carrying chalcone moiety as hybrid molecules.
Abou-Zied HA; Youssif BGM; Mohamed MFA; Hayallah AM; Abdel-Aziz M
Bioorg Chem; 2019 Aug; 89():102997. PubMed ID: 31136902
[TBL] [Abstract][Full Text] [Related]
4. New oxadiazoles with selective-COX-2 and EGFR dual inhibitory activity: Design, synthesis, cytotoxicity evaluation and in silico studies.
El-Sayed NA; Nour MS; Salem MA; Arafa RK
Eur J Med Chem; 2019 Dec; 183():111693. PubMed ID: 31539778
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of Benzamide-Chalcone Derivatives as EGFR/CDK2 Inhibitor: Synthesis, In-Vitro Inhibition, and Molecular Modeling Studies.
Joshi A; Bhojwani H; Wagal O; Begwani K; Joshi U; Sathaye S; Kanchan D
Anticancer Agents Med Chem; 2022; 22(2):328-343. PubMed ID: 33858315
[TBL] [Abstract][Full Text] [Related]
6. New 1,3,4-oxadiazole-chalcone/benzimidazole hybrids as potent antiproliferative agents.
Hagar FF; Abbas SH; Abdelhamid D; Gomaa HAM; Youssif BGM; Abdel-Aziz M
Arch Pharm (Weinheim); 2023 Feb; 356(2):e2200357. PubMed ID: 36351754
[TBL] [Abstract][Full Text] [Related]
7. Design, synthesis, chemical characterization, biological evaluation, and docking study of new 1,3,4-oxadiazole homonucleoside analogs.
El Mansouri AE; Maatallah M; Ait Benhassou H; Moumen A; Mehdi A; Snoeck R; Andrei G; Zahouily M; Lazrek HB
Nucleosides Nucleotides Nucleic Acids; 2020; 39(8):1088-1107. PubMed ID: 32397827
[TBL] [Abstract][Full Text] [Related]
8. 2-Thiopyrimidine/chalcone hybrids: design, synthesis, ADMET prediction, and anticancer evaluation as STAT3/STAT5a inhibitors.
Lamie PF; Philoppes JN
J Enzyme Inhib Med Chem; 2020 Dec; 35(1):864-879. PubMed ID: 32208772
[TBL] [Abstract][Full Text] [Related]
9. Rational design-aided discovery of novel 1,2,4-oxadiazole derivatives as potential EGFR inhibitors.
Unadkat V; Rohit S; Parikh P; Sanna V; Singh S
Bioorg Chem; 2021 Sep; 114():105124. PubMed ID: 34328857
[TBL] [Abstract][Full Text] [Related]
10. Quinazoline-chalcone hybrids as HDAC/EGFR dual inhibitors: Design, synthesis, mechanistic, and in-silico studies of potential anticancer activity against multiple myeloma.
Mansour MA; AboulMagd AM; Abbas SH; Abdel-Aziz M; Abdel-Rahman HM
Arch Pharm (Weinheim); 2024 May; 357(5):e2300626. PubMed ID: 38297894
[TBL] [Abstract][Full Text] [Related]
11. Design, synthesis and anticancer evaluation of thieno[2,3-d]pyrimidine derivatives as dual EGFR/HER2 inhibitors and apoptosis inducers.
Elmetwally SA; Saied KF; Eissa IH; Elkaeed EB
Bioorg Chem; 2019 Jul; 88():102944. PubMed ID: 31051400
[TBL] [Abstract][Full Text] [Related]
12. 1,2,4-Oxadiazole derivatives targeting EGFR and c-Met degradation in TKI resistant NSCLC.
Dokla EME; Fang CS; Abouzid KAM; Chen CS
Eur J Med Chem; 2019 Nov; 182():111607. PubMed ID: 31446247
[TBL] [Abstract][Full Text] [Related]
13. Design, synthesis and biological evaluation of a new series of thiazolyl-pyrazolines as dual EGFR and HER2 inhibitors.
Sever B; Altıntop MD; Radwan MO; Özdemir A; Otsuka M; Fujita M; Ciftci HI
Eur J Med Chem; 2019 Nov; 182():111648. PubMed ID: 31493743
[TBL] [Abstract][Full Text] [Related]
14. Synthesis, EGFR Inhibition and Anti-cancer Activity of New 3,6-dimethyl-1-phenyl-4-(substituted-methoxy)pyrazolo[3,4-d] pyrimidine Derivatives.
Bakr RB; Mehany ABM; Abdellatif KRA
Anticancer Agents Med Chem; 2017; 17(10):1389-1400. PubMed ID: 28270084
[TBL] [Abstract][Full Text] [Related]
15. A Review: Discovering 1,3,4-oxadiazole and Chalcone Nucleus for Cytotoxicity / EGFR Inhibitory Anticancer Activity.
Patil S; Bhandari S
Mini Rev Med Chem; 2022; 22(5):805-820. PubMed ID: 34477516
[TBL] [Abstract][Full Text] [Related]
16. Design, synthesis, in vitro and in silico evaluation of a new series of oxadiazole-based anticancer agents as potential Akt and FAK inhibitors.
Altıntop MD; Sever B; Akalın Çiftçi G; Turan-Zitouni G; Kaplancıklı ZA; Özdemir A
Eur J Med Chem; 2018 Jul; 155():905-924. PubMed ID: 29966916
[TBL] [Abstract][Full Text] [Related]
17. An in vivo active 1,2,5-oxadiazole Pt(II) complex: A promising anticancer agent endowed with STAT3 inhibitory properties.
Porta F; Facchetti G; Ferri N; Gelain A; Meneghetti F; Villa S; Barlocco D; Masciocchi D; Asai A; Miyoshi N; Marchianò S; Kwon BM; Jin Y; Gandin V; Marzano C; Rimoldi I
Eur J Med Chem; 2017 May; 131():196-206. PubMed ID: 28324784
[TBL] [Abstract][Full Text] [Related]
18. Design, synthesis and anticancer evaluation of 1H-pyrazolo[3,4-d]pyrimidine derivatives as potent EGFR
Gaber AA; Bayoumi AH; El-Morsy AM; Sherbiny FF; Mehany ABM; Eissa IH
Bioorg Chem; 2018 Oct; 80():375-395. PubMed ID: 29986185
[TBL] [Abstract][Full Text] [Related]
19. Novel pyrazolo[3,4-d]pyrimidines: design, synthesis, anticancer activity, dual EGFR/ErbB2 receptor tyrosine kinases inhibitory activity, effects on cell cycle profile and caspase-3-mediated apoptosis.
Maher M; Kassab AE; Zaher AF; Mahmoud Z
J Enzyme Inhib Med Chem; 2019 Dec; 34(1):532-546. PubMed ID: 30688116
[TBL] [Abstract][Full Text] [Related]
20. Synthesis of Novel Thieno[2,3-d]pyrimidine Derivatives and Evaluation of Their Cytotoxicity and EGFR Inhibitory Activity.
Adly ME; Gedawy EM; El-Malah AA; El-Telbany FA
Anticancer Agents Med Chem; 2018; 18(5):747-756. PubMed ID: 29366427
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
